Effects of Table Tennis for People With Parkinson's Disease

May 30, 2024 updated by: Helena Fernández-Lago, Universitat de Lleida

Motor and Cognitive Effects of Table Tennis on Parkinson's Disease: Pilot Controlled Trial

Quasi-experimental, controlled, non-randomised two-arm pilot, with an experimental group (table tennis exercise) and an active control group (cognitive training based on board games).

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Quasi-experimental, controlled, non-randomised two-arm pilot, with an experimental group (table tennis exercise) and an active control group (cognitive training based on board games). Interventions in both groups will take place twice a week for 6 weeks (12 sessions in total). The main variables to be assessed will be motor and cognitive. As secondary variables, clinical and daily life aspects will be assessed. As results, it is expected that the experimental group will obtain improvements in motor variables compared to the control group after receiving the interventions. However, improvements in cognitive variables and secondary variables are expected to be similar in both groups.

Study Type

Interventional

Enrollment (Estimated)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Diagnosis of Parkinson's Disease based on the UK PD Society Brain Bank Criteria
  • Stage I to III on the Hoehn and Yahr scale
  • Ability to walk for 10 minutes unassisted

Exclusion Criteria:

  • Score of under 23 on the Mini-Mental State Examination
  • Severe Visual or Auditory deficits
  • Cardiovascular conditions that impede physical activity
  • Brain surgery

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Table Tennis
Participants will follow supervised Table Tennis sessions lasting 60 minutes during 6 weeks, for a total of 12 sessions.
Other: Exercise and cognitive training interventino
Exercise and cognitive training based on Table tennis and Tabletop games.
Experimental: Tabletop Games
Participants will follow supervised Tabletop Game sessions lasting 60 minutes during 6 weeks, for a total of 12 sessions.
Other: Exercise and cognitive training interventino
Exercise and cognitive training based on Table tennis and Tabletop games.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Amplitude of Center of Pressure under simple conditions
Time Frame: Assessed before starting the intervention (T0) and 6 weeks later (T0 + 6 weeks).
Assessment of amplitude of Center of Pressure (in mm) during balance testing using OPAL Sensors (APDM, Oregon, USA).
Assessed before starting the intervention (T0) and 6 weeks later (T0 + 6 weeks).
Amplitude of Center of Pressure under Dual Task conditions (Motor)
Time Frame: Assessed before starting the intervention (T0) and 6 weeks later (T0 + 6 weeks).
Assessment of amplitude of Center of Pressure (in mm) during balance testing under concurrent cognitive tasks (Motor, by holding a glass of water on a tray) using OPAL Sensors (APDM, Oregon, USA).
Assessed before starting the intervention (T0) and 6 weeks later (T0 + 6 weeks).
Amplitude of Center of Pressure under Dual Task conditions (Arithmetic)
Time Frame: Assessed before starting the intervention (T0) and 6 weeks later (T0 + 6 weeks).
Assessment of amplitude of Center of Pressure (in mm) during balance testing under concurrent cognitive tasks (Arithmetic, by concurrently substracting 7 from a random number) using OPAL Sensors (APDM, Oregon, USA).
Assessed before starting the intervention (T0) and 6 weeks later (T0 + 6 weeks).
Amplitude of Center of Pressure under Dual Task conditions (Verbal)
Time Frame: Assessed before starting the intervention (T0) and 6 weeks later (T0 + 6 weeks).
Assessment of amplitude of Center of Pressure (in mm) during balance testing under concurrent cognitive tasks (Verbal, by naming words starting by a random letter) using OPAL Sensors (APDM, Oregon, USA).
Assessed before starting the intervention (T0) and 6 weeks later (T0 + 6 weeks).
Trail-Making Test
Time Frame: Assessed before starting the intervention (T0) and 6 weeks later (T0 + 6 weeks).
Assessment of Trail-Making Test parts A and B
Assessed before starting the intervention (T0) and 6 weeks later (T0 + 6 weeks).

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
United Parkinson's Disease Rating Scale - Part III
Time Frame: Assessed before starting the intervention (T0) and 6 weeks later (T0 + 6 weeks).
Assessment of Motor symptoms of Parkinson's Disease with a predetermined assessment
Assessed before starting the intervention (T0) and 6 weeks later (T0 + 6 weeks).
Montreal Cognitive Assessment
Time Frame: Assessed before starting the intervention (T0) and 6 weeks later (T0 + 6 weeks).
Assessment of cognitive status to detect Mild Cognitive Impairment with a preset questionnaire.
Assessed before starting the intervention (T0) and 6 weeks later (T0 + 6 weeks).
Parkinson's Disease Questionnaire - 8
Time Frame: Assessed before starting the intervention (T0) and 6 weeks later (T0 + 6 weeks).
Assessment of Quality of Life for people with Parkinson's Disease through a self-administered questionnaire
Assessed before starting the intervention (T0) and 6 weeks later (T0 + 6 weeks).
Timed Up and Go test
Time Frame: Assessed before starting the intervention (T0) and 6 weeks later (T0 + 6 weeks).
Assessment of gait mobility and fall risk by getting up from a chair, walking 3 meters, turning back and sitting again.
Assessed before starting the intervention (T0) and 6 weeks later (T0 + 6 weeks).
Falls Efficacy Scale International
Time Frame: Assessed before starting the intervention (T0) and 6 weeks later (T0 + 6 weeks).
Assessment of perceived fall risk with a predetermined questionnaire.
Assessed before starting the intervention (T0) and 6 weeks later (T0 + 6 weeks).

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Universitat de Lleida

Collaborators

Club Tennis Taula Borges Blanques
Asociació de Parkinson de les Terres de Lleida

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2023

Primary Completion (Estimated)

June 30, 2025

Study Completion (Estimated)

June 30, 2026

Study Registration Dates

First Submitted

March 12, 2024

First Submitted That Met QC Criteria

May 30, 2024

First Posted (Actual)

June 5, 2024

Study Record Updates

Last Update Posted (Actual)

June 5, 2024

Last Update Submitted That Met QC Criteria

May 30, 2024

Last Verified

May 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2023CRINDESTABC

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Parkinson Disease

Clinical Trials on Exercise and cognitive training interventino

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uganda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe